PharmaNutra SpA, the Healthcare sector company, was revisited by a Wall Street analyst on November 21. Analyst Corentin Marty from TP ICAP MIDCAP reiterated a Buy rating on the stock and has a €74.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Corentin Marty has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s strong performance and future potential. The company has shown impressive growth in the United States, with its product SiderAL becoming one of the fastest-growing iron supplements on Amazon US. This growth is supported by a significant increase in revenue for the PHN USA subsidiary, which has seen a sixfold increase compared to the previous year.
Furthermore, PharmaNutra’s strategic revisions in 2025 have yielded almost immediate positive results, with a substantial portion of revenue generated in the third quarter alone. The company’s ability to maintain a high customer satisfaction rating, despite its premium pricing, underscores the value and effectiveness of its products. Additionally, the stock is currently undervalued compared to historical averages and peers, presenting a strong revaluation potential. These factors collectively justify the Buy recommendation, as they indicate a promising outlook for the company’s growth and profitability.
In another report released on November 12, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a €57.00 price target.
PHN’s price has also changed slightly for the past six months – from EUR51.800 to EUR50.200, which is a -3.09% drop .